Evidence map›Paper›PMID 34153671›Full record

Observational studyInternational immunopharmacology2021

A single center experience of intravenous immunoglobulin treatment in Covid-19.

Ahmet Omma, Abdulsamet Erden, Berkan Armağan, Serdar Can Güven, Özlem Karakaş, Enes Seyda Şahiner, Deniz Erdem, Seval İzdeş, İhsan Ateş, Orhan Küçükşahin

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Other Immunomodulatory Treatment for Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024
    Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ahmet OmmaMinistry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara 06800, Turkey.
Abdulsamet ErdenMinistry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara 06800, Turkey.
Berkan ArmağanMinistry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara 06800, Turkey.
Serdar Can GüvenMinistry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara 06800, Turkey. Electronic address: drserdarguven@gmail.com.
Özlem KarakaşMinistry of Health Ankara City Hospital, Clinic of Rheumatology, Ankara 06800, Turkey.
Enes Seyda ŞahinerMinistry of Health Ankara City Hospital, Clinic of Internal Medicine, Ankara 06800, Turkey.
Deniz ErdemUniversity of Health Sciences, School of Medicine, Ankara City Hospital, Department of Anesthesia and Resuscitation, Ankara 06800, Turkey.
Seval İzdeşYıldırım Beyazıt University, School of Medicine, Department of Anesthesiology and Reanimation-Critical Care, Ankara 06800, Turkey.
İhsan AteşUniversity of Health Sciences, School of Medicine, Ankara City Hospital, Department of Internal Medicine, Ankara 06800, Turkey.
Orhan KüçükşahinYıldırım Beyazıt University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara 06800, Turkey.
Ministry of Health · TRAnkara Yıldırım Beyazıt University · TRSağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntravenous immunoglobulins (IVIg) have been used in management of severe Covid-19. Here in this study, we report our single-center experience regarding IVIg treatment in management of severe Covid-19. MATERIALS AND

methodAmong hospitalized adult Covid-19 patients between April 1 and December 31, 2020, patients with confirmed diagnosis of Covid-19 who had Brescia-COVID respiratory severity scale score ≥ 3, hyperinflammation and received IVIg treatment in addition to standard of care were retrospectively investigated. We grouped IVIg recipients into three according to reasons for IVIg administration: Group 1 patients requiring anti-inflammatory treatment but complicated with secondary infection and/or sepsis , group 2 patients with Covid-19 related complications including progressive disease refractory to other anti-inflammatory agents, myocarditis, adult multisystem inflammatory syndrome, hemophagocytic lymphohystiocytosis like syndrome and group 3 patients with other complications non-specific to Covid-19. Mortality and clinical data was compared among groups.

resultsA total of 46 IVIg recipients were enrolled. Group 1 comprised 17 (36.9%), group 2 comprised 18 (39.1%) and group 3 comprised 11 (23.9%) patients. No significant differences in means of age, gender and comorbidities were observed among groups. Mortality was significantly lower in group 3 when compared to group 1 (64.7% vs 18.2%, p = 0.016) and close to significance when compared to group 2 (50% vs 18.2% p = 0.087).

conclusionsIVIg seemed to be used mostly in severe, refractory and complicated cases in our population. As a rescue agent in severe cases refractory to other anti-inflammatory strategies, 33.7% survival rate was observed with IVIg.

Indexed as

COVID-19 Drug TreatmentAdministration, IntravenousAdultAgedAged, 80 and overCOVID-19Cross-Sectional StudiesFemaleHumansImmunoglobulins, IntravenousMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexTime FactorsTreatment OutcomeImmunoglobulins, IntravenousCovid-19Cytokine stormIntravenous immunoglobulinMortality

Identifiers

PMID34153671
PMCPMC8200303
OpenAlexW3165893326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.